Neurocrine Biosciences Inc
Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.
Earnings per share grew at a 50.0% CAGR.
Current Price
$131.78
+0.08%GoodMoat Value
$213.39
61.9% undervaluedNeurocrine Biosciences Inc (NBIX) Stock Chart
NBIX Interactive Stock Chart
Interactive stock chart for Neurocrine Biosciences Inc (NBIX) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $131.78. 52-week high: $155.63. 52-week low: $109.75. 50-day moving average: $130.25. 200-day moving average: $137.33.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for NBIX. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Neurocrine Biosciences Inc's investment potential.